1. Ahren B, et al. Postprandial glucagon reductions correlate to reductions in postprandial glucose and glycated hemoglobin with lixisenatide treatment in type 2 diabetes mellitus: A Post Hoc Analysis. Diabetes Ther. 2016 Jun 18.
  2. Yabe D, et al. Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials. J Diabetes Complications. 2016 May 24.
  3. Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57
  4. Holland EJ, et al. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials. Curr Med Res Opin. 2016 Jul 8:1-24
  5. Sheppard JD, et al. Lifitegrast ophthalmic solution 5% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014 Feb;121(2):475-83
  6. Tauber J, et al. Lifitegrast ophthalmic solution 5% versus placebo for treatment of dry eye disease: Results of the randomized phase III OPUS-2 study. Ophthalmology. 2015 Dec;122(12):2423-31.
  7. Donnefeld ED, et al. Safety of lifitegrast ophthalmic solution 5% in patients with dry eye disease: A 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016 Jun;35(6):741-8.
  8. Syndros (dronabinol) prescribing information. Insys Therapeutics, Inc. Chandler, AZ. July 2016.
  9. Xolair (omalizumab) prescribing information. Genentech. South San Francisco, CA. July 2016.
  10. Chang CY, Hersh PS. Corneal collagen cross-linking: a review of 1-year outcomes. Eye Contact Lens. 2014 Nov;40(6):345-52.
  11. Namzaric (memantine/donepezil) prescribing information. Allergan USA, Inc. Irvine, CA. July 2016.
  12. Berinert (C1 esterase inhibitor) prescribing information. CSL Behring LLC. Kankakee, IL July 2016.

Contributor Information


Mary L Windle, PharmD
Editor-in-Chief, Medscape Drug Reference